Symbols / ALLO
ALLO Chart
About
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 514.63M |
| Enterprise Value | 347.58M | Income | -212.02M | Sales | — |
| Book/sh | 1.41 | Cash/sh | 1.12 | Dividend Yield | — |
| Payout | 0.00% | Employees | 226 | IPO | — |
| P/E | — | Forward P/E | -2.59 | PEG | — |
| P/S | inf | P/B | 1.62 | P/C | — |
| EV/EBITDA | -1.64 | EV/Sales | — | Quick Ratio | 7.99 |
| Current Ratio | 8.19 | Debt/Eq | 27.00 | LT Debt/Eq | — |
| EPS (ttm) | -0.98 | EPS next Y | -0.89 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-19 | ROA | -27.34% |
| ROE | -54.43% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 224.73M |
| Shs Float | 156.23M | Short Float | 10.08% | Short Ratio | 3.11 |
| Short Interest | — | 52W High | 2.32 | 52W Low | 0.86 |
| Beta | 0.60 | Avg Volume | 4.55M | Volume | 6.62M |
| Target Price | $7.38 | Recom | Buy | Prev Close | $2.08 |
| Price | $2.29 | Change | 10.10% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$7.38
Mean price target
2. Current target
$2.29
Latest analyst target
3. DCF / Fair value
$-6.72
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.29
Low
$1.60
High
$14.00
Mean
$7.38
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-09 | up | Citizens | Market Perform → Market Outperform | $5 |
| 2026-01-07 | init | UBS | — → Buy | $8 |
| 2025-10-10 | down | JP Morgan | Neutral → Underweight | — |
| 2025-08-04 | reit | JMP Securities | Market Perform → Market Perform | — |
| 2025-08-04 | down | JP Morgan | Overweight → Neutral | — |
| 2025-08-01 | main | Oppenheimer | Outperform → Outperform | $7 |
| 2025-05-15 | main | Citigroup | Buy → Buy | $4 |
| 2025-05-14 | main | Truist Securities | Buy → Buy | $10 |
| 2025-05-14 | main | Piper Sandler | Overweight → Overweight | $7 |
| 2025-05-14 | reit | RBC Capital | Outperform → Outperform | $10 |
| 2025-05-14 | main | Oppenheimer | Outperform → Outperform | $9 |
| 2025-05-14 | main | Baird | Outperform → Outperform | $9 |
| 2025-03-19 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-03-14 | main | Canaccord Genuity | Buy → Buy | $14 |
| 2025-03-14 | reit | RBC Capital | Outperform → Outperform | $10 |
| 2025-03-14 | up | Citizens Capital Markets | Market Perform → Market Outperform | $5 |
| 2024-11-14 | main | Piper Sandler | Overweight → Overweight | $9 |
| 2024-11-08 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-10-30 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
- $ALLO stock is up 17% today. Here's what we see in our data. - Quiver Quantitative ue, 17 Feb 2026 19
- Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance Mon, 26 Jan 2026 08
- Allogene (NASDAQ: ALLO) to join 3 conferences: TD Cowen, Jefferies London, Piper Sandler - Stock Titan Mon, 10 Nov 2025 08
- Allogene stock rises after favorable arbitration ruling reaffirms therapy rights - Investing.com Mon, 15 Dec 2025 08
- Allogene, Pliant down as J.P. Morgan cuts to Underweight on uncertain outlook - Seeking Alpha Fri, 10 Oct 2025 07
- JP Morgan Downgrades Allogene Therapeutics (ALLO) to Underweight - GuruFocus Fri, 10 Oct 2025 07
- Insider Sale: SVP of $ALLO Sells 7,549 Shares - Quiver Quantitative Wed, 04 Feb 2026 08
- Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? - Yahoo Finance Wed, 11 Feb 2026 08
- Cancer-focused CAR T developer Allogene joins 2 Q1 investor events - Stock Titan hu, 05 Feb 2026 08
- UBS initiates coverage on Allogene stock with Buy rating, $8 price target - Investing.com Wed, 07 Jan 2026 08
- Allogene Therapeutics: Important Catalysts Guided For Early 2026 (NASDAQ:ALLO) - Seeking Alpha hu, 14 Aug 2025 07
- Why Is Allogene Therapeutics (ALLO) Up 9.4% Since Last Earnings Report? - Yahoo Finance Fri, 12 Sep 2025 07
- Allogene Therapeutics (NASDAQ: ALLO) sets Q3 2025 results; webcast at 2 p.m. PT - Stock Titan hu, 30 Oct 2025 07
- $ALLO stock is down 13% today. Here's what we see in our data. | ALLO Stock News - Quiver Quantitative Mon, 26 Jan 2026 08
- Allogene Therapeutics’ SWOT analysis: stock faces challenges amid promising pipeline - Investing.com ue, 02 Sep 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 22900 | 40304.0 | — | Sale at price 1.76 per share. | DOUGLAS EARL MARTIN | General Counsel | — | 2026-02-02 00:00:00 | D |
| 1 | 95269 | 171484.0 | — | Sale at price 1.80 per share. | CHANG DAVID D | Chief Executive Officer | — | 2026-02-02 00:00:00 | D |
| 2 | 24001 | 42242.0 | — | Sale at price 1.76 per share. | PARKER GEOFFREY M | Chief Financial Officer | — | 2026-02-02 00:00:00 | D |
| 3 | 4167 | 7167.0 | — | Sale at price 1.72 per share. | YOSHIYAMA ANNIE | Officer | — | 2026-02-02 00:00:00 | D |
| 4 | 35700 | 63189.0 | — | Sale at price 1.77 per share. | ROBERTS ZACHARY | Officer | — | 2026-02-02 00:00:00 | D |
| 5 | 7549 | 13060.0 | — | Sale at price 1.73 per share. | BENESKI BENJAMIN MACHINAS | Chief Technology Officer | — | 2026-02-02 00:00:00 | D |
| 6 | 26269 | 40980.0 | — | Sale at price 1.56 per share. | ROBERTS ZACHARY | Officer | — | 2026-01-21 00:00:00 | D |
| 7 | 47700 | nan | — | — | KAZAM JOSHUA A | Director | — | 2025-12-18 00:00:00 | D |
| 8 | 786 | 959.0 | — | Sale at price 1.22 per share. | BENESKI BENJAMIN MACHINAS | Chief Technology Officer | — | 2025-11-17 00:00:00 | D |
| 9 | 36744 | 46169.0 | — | Sale at price 1.26 per share. | PARKER GEOFFREY M | Chief Financial Officer | — | 2025-10-21 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -3.30M | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -227.61M | -299.82M | -321.24M | -169.74M |
| TotalUnusualItems | -15.72M | -13.24M | ||
| TotalUnusualItemsExcludingGoodwill | -15.72M | -13.24M | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -257.59M | -327.26M | -340.41M | -182.05M |
| ReconciledDepreciation | 13.64M | 14.20M | 14.29M | 10.45M |
| EBITDA | -243.33M | -313.07M | -321.24M | -169.74M |
| EBIT | -256.97M | -327.26M | -335.54M | -180.19M |
| NetInterestIncome | 19.97M | 18.31M | 4.57M | 1.71M |
| InterestExpense | 181.00K | 0.00 | ||
| InterestIncome | 20.15M | 18.31M | 4.57M | 1.71M |
| NormalizedIncome | -245.17M | -314.02M | -340.41M | -182.05M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -257.59M | -327.26M | -340.41M | -182.05M |
| TotalExpenses | 257.50M | 314.59M | 335.69M | 294.28M |
| TotalOperatingIncomeAsReported | -273.20M | -327.74M | -335.54M | -180.19M |
| DilutedAverageShares | 194.81M | 156.93M | 143.15M | 135.82M |
| BasicAverageShares | 194.81M | 156.93M | 143.15M | 135.82M |
| DilutedEPS | -1.32 | -2.09 | -2.32 | -1.89 |
| BasicEPS | -1.32 | -2.09 | -2.32 | -1.89 |
| DilutedNIAvailtoComStockholders | -257.59M | -327.26M | -340.41M | -182.05M |
| NetIncomeCommonStockholders | -257.59M | -327.26M | -340.41M | -182.05M |
| NetIncome | -257.59M | -327.26M | -340.41M | -182.05M |
| NetIncomeIncludingNoncontrollingInterests | -257.59M | -327.26M | -340.41M | -182.05M |
| NetIncomeContinuousOperations | -257.59M | -327.26M | -340.41M | -182.05M |
| TaxProvision | 443.00K | 0.00 | 0.00 | |
| PretaxIncome | -257.15M | -327.26M | -340.41M | -182.05M |
| OtherIncomeExpense | -19.64M | -31.08M | -9.44M | -3.57M |
| OtherNonOperatingIncomeExpenses | -3.92M | -17.84M | -9.44M | -3.57M |
| SpecialIncomeCharges | -15.72M | -13.24M | ||
| ImpairmentOfCapitalAssets | 15.72M | 13.24M | ||
| NetNonOperatingInterestIncomeExpense | 19.97M | 18.31M | 4.57M | 1.71M |
| InterestExpenseNonOperating | 181.00K | 0.00 | ||
| InterestIncomeNonOperating | 20.15M | 18.31M | 4.57M | 1.71M |
| OperatingIncome | -257.48M | -314.49M | -335.54M | -180.19M |
| OperatingExpense | 257.50M | 314.59M | 335.69M | 294.28M |
| ResearchAndDevelopment | 192.30M | 242.91M | 256.39M | 220.18M |
| SellingGeneralAndAdministration | 65.20M | 71.67M | 79.31M | 74.11M |
| GeneralAndAdministrativeExpense | 65.20M | 71.67M | 79.31M | 74.11M |
| OtherGandA | 65.20M | 71.67M | 79.31M | 74.11M |
| TotalRevenue | 22.00K | 95.00K | 156.00K | 114.09M |
| OperatingRevenue | 22.00K | 95.00K | 156.00K | 114.09M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 212.21M | 168.64M | 144.44M | 142.62M |
| ShareIssued | 212.21M | 168.64M | 144.44M | 142.62M |
| TotalDebt | 90.76M | 95.12M | 101.12M | 73.13M |
| TangibleBookValue | 422.18M | 512.23M | 666.88M | 925.20M |
| InvestedCapital | 422.18M | 512.23M | 666.88M | 925.20M |
| WorkingCapital | 267.86M | 422.04M | 475.10M | 423.42M |
| NetTangibleAssets | 422.18M | 512.23M | 666.88M | 925.20M |
| CapitalLeaseObligations | 90.76M | 95.12M | 101.12M | 73.13M |
| CommonStockEquity | 422.18M | 512.23M | 666.88M | 925.20M |
| TotalCapitalization | 422.18M | 512.23M | 666.88M | 925.20M |
| TotalEquityGrossMinorityInterest | 422.18M | 512.23M | 666.88M | 925.20M |
| StockholdersEquity | 422.18M | 512.23M | 666.88M | 925.20M |
| GainsLossesNotAffectingRetainedEarnings | -89.00K | -955.00K | -9.93M | -2.57M |
| OtherEquityAdjustments | -89.00K | -955.00K | -9.93M | -2.57M |
| RetainedEarnings | -1.82B | -1.56B | -1.23B | -894.55M |
| AdditionalPaidInCapital | 2.24B | 2.08B | 1.91B | 1.82B |
| CapitalStock | 212.00K | 169.00K | 144.00K | 142.00K |
| CommonStock | 212.00K | 169.00K | 144.00K | 142.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 126.53M | 130.60M | 154.70M | 125.63M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 91.01M | 93.53M | 100.97M | 77.72M |
| OtherNonCurrentLiabilities | 7.76M | 5.18M | 5.85M | 7.79M |
| LongTermDebtAndCapitalLeaseObligation | 83.25M | 88.35M | 95.12M | 69.93M |
| LongTermCapitalLeaseObligation | 83.25M | 88.35M | 95.12M | 69.93M |
| CurrentLiabilities | 35.52M | 37.08M | 53.73M | 47.91M |
| OtherCurrentLiabilities | 86.00K | |||
| CurrentDeferredLiabilities | 86.00K | 95.00K | 156.00K | |
| CurrentDeferredRevenue | 86.00K | 95.00K | 156.00K | |
| CurrentDebtAndCapitalLeaseObligation | 7.51M | 6.78M | 6.00M | 3.20M |
| CurrentCapitalLeaseObligation | 7.51M | 6.78M | 6.00M | 3.20M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 12.15M | 12.66M | 17.93M | 16.13M |
| PayablesAndAccruedExpenses | 15.87M | 17.55M | 29.70M | 28.43M |
| CurrentAccruedExpenses | 10.47M | 11.66M | 15.81M | 18.17M |
| Payables | 5.39M | 5.90M | 13.89M | 10.26M |
| AccountsPayable | 5.39M | 5.90M | 13.89M | 10.26M |
| TotalAssets | 548.71M | 642.84M | 821.58M | 1.05B |
| TotalNonCurrentAssets | 245.32M | 183.72M | 292.75M | 579.50M |
| OtherNonCurrentAssets | 33.39M | 16.90M | 19.86M | 16.11M |
| InvestmentsAndAdvances | 80.67M | 3.65M | 76.47M | 382.38M |
| InvestmentinFinancialAssets | 80.67M | 0.00 | 59.15M | 352.18M |
| AvailableForSaleSecurities | 80.67M | 59.15M | 352.18M | |
| LongTermEquityInvestment | 0.00 | 3.65M | 17.32M | 30.20M |
| NetPPE | 131.26M | 163.18M | 196.43M | 181.02M |
| AccumulatedDepreciation | -62.54M | -51.08M | -36.88M | -23.36M |
| GrossPPE | 193.80M | 214.26M | 233.32M | 204.38M |
| Leases | 108.13M | 108.62M | 108.55M | 108.35M |
| ConstructionInProgress | 0.00 | 28.00K | 39.00K | |
| OtherProperties | 76.80M | 96.86M | 116.19M | 87.70M |
| MachineryFurnitureEquipment | 8.87M | 8.78M | 8.54M | 8.29M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 303.39M | 459.12M | 528.82M | 471.32M |
| OtherCurrentAssets | 10.91M | 10.42M | 11.50M | 14.02M |
| PrepaidAssets | 14.02M | |||
| CashCashEquivalentsAndShortTermInvestments | 292.48M | 448.70M | 517.32M | 457.30M |
| OtherShortTermInvestments | 217.26M | 365.54M | 455.42M | 283.99M |
| CashAndCashEquivalents | 75.22M | 83.16M | 61.90M | 173.31M |
| CashEquivalents | 78.54M | |||
| CashFinancial | 4.62M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -200.99M | -239.25M | -225.71M | -206.26M |
| IssuanceOfCapitalStock | 112.05M | 91.11M | 0.00 | 0.00 |
| CapitalExpenditure | -694.00K | -1.52M | -5.19M | -21.45M |
| EndCashPosition | 85.51M | 93.45M | 72.20M | 183.61M |
| BeginningCashPosition | 93.45M | 72.20M | 183.61M | 192.80M |
| ChangesInCash | -7.94M | 21.25M | -111.41M | -9.19M |
| FinancingCashFlow | 116.67M | 95.69M | 2.95M | 11.96M |
| CashFlowFromContinuingFinancingActivities | 116.67M | 95.69M | 2.95M | 11.96M |
| NetOtherFinancingCharges | 2.28M | |||
| ProceedsFromStockOptionExercised | 2.35M | 4.58M | 2.95M | 11.96M |
| NetCommonStockIssuance | 112.05M | 91.11M | 0.00 | 0.00 |
| CommonStockIssuance | 112.05M | 91.11M | 0.00 | 0.00 |
| InvestingCashFlow | 75.69M | 163.29M | 106.16M | 163.66M |
| CashFlowFromContinuingInvestingActivities | 75.69M | 163.29M | 106.16M | 163.66M |
| NetInvestmentPurchaseAndSale | 76.38M | 164.81M | 111.35M | 202.81M |
| SaleOfInvestment | 437.86M | 603.43M | 359.46M | 728.39M |
| PurchaseOfInvestment | -361.48M | -438.63M | -248.11M | -525.58M |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | -17.71M | |
| PurchaseOfBusiness | 0.00 | 0.00 | -17.71M | |
| NetPPEPurchaseAndSale | -694.00K | -1.52M | -5.19M | -21.45M |
| PurchaseOfPPE | -694.00K | -1.52M | -5.19M | -21.45M |
| OperatingCashFlow | -200.30M | -237.73M | -220.52M | -184.81M |
| CashFlowFromContinuingOperatingActivities | -200.30M | -237.73M | -220.52M | -184.81M |
| ChangeInWorkingCapital | -24.80M | -21.31M | 3.90M | -31.95M |
| ChangeInOtherWorkingCapital | -20.77M | -3.00K | -21.00K | -38.30M |
| ChangeInOtherCurrentLiabilities | -6.05M | -6.61M | -1.88M | 910.00K |
| ChangeInOtherCurrentAssets | 4.28M | -1.46M | -3.33M | -646.00K |
| ChangeInPayablesAndAccruedExpense | -1.76M | -14.32M | 6.62M | 2.88M |
| ChangeInAccruedExpense | -1.26M | -6.82M | 1.75M | 3.65M |
| ChangeInPayable | -503.00K | -7.50M | 4.87M | -767.00K |
| ChangeInAccountPayable | -503.00K | -7.50M | 4.87M | -767.00K |
| ChangeInPrepaidAssets | -492.00K | 1.09M | 2.52M | 3.20M |
| OtherNonCashItems | 5.25M | 6.58M | 2.33M | -73.13M |
| StockBasedCompensation | 51.74M | 65.95M | 83.60M | 80.82M |
| AssetImpairmentCharge | 17.67M | 20.25M | ||
| AmortizationOfSecurities | -8.35M | -6.81M | 2.89M | 6.96M |
| DeferredTax | 443.00K | 0.00 | 0.00 | |
| DeferredIncomeTax | 443.00K | 0.00 | 0.00 | |
| DepreciationAmortizationDepletion | 13.64M | 14.20M | 14.29M | 10.45M |
| DepreciationAndAmortization | 13.64M | 14.20M | 14.29M | 10.45M |
| AmortizationCashFlow | 0.00 | 0.00 | ||
| AmortizationOfIntangibles | 0.00 | 0.00 | ||
| Depreciation | 14.29M | 10.45M | ||
| OperatingGainsLosses | 1.69M | 10.67M | 12.88M | 4.09M |
| EarningsLossesFromEquityInvestments | 1.69M | 10.67M | 12.88M | 4.09M |
| NetIncomeFromContinuingOperations | -257.59M | -327.26M | -340.41M | -182.05M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ALLO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|